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Background: In this study, the effects of an enteral diet enriched with eicosapentaenoic acid (EPA), γ-linolenic acid
(GLA), and antioxidants were compared with a standard enteral diet in critically ill patients with sepsis-induced
acute respiratory distress syndrome (ARDS).
Methods: This study was a single-center, prospective, randomized, single-blind, controlled trial in our Advanced
Critical Care Center. Patients were randomized to receive a continuous EPA, GLA, and antioxidant-enriched diet
(study group), or an isocaloric standard diet (control group).
Results: Twenty-three of 46 patients were in the study group, and the other 23 were in the control group.
Duration of mechanical ventilation, incidence of new nosocomial infections, changes over time in Sequential Organ
Failure Assessment (SOFA) scores, and 60-day mortality were not significantly different between the two groups.
The ratio of partial pressure of oxygen to fraction of inspired oxygen on day 7 was significantly higher in the study
group (233.0 [185.5–282.8] vs. 274.0 [225.5–310.8], p = 0.021). Duration of ICU stay was significantly shorter in the
study group than in the control group (24.0 [20.0–30.0] vs. 15.0 [11.0–24.0], p = 0.008).
Conclusions: An enteral diet enriched with EPA, GLA, and antioxidants did not improve duration of mechanical
ventilation, SOFA score, incidence of new nosocomial infections, or mortality but did favorably influence duration of
ICU stay in critically ill patients with sepsis-induced ARDS.
Keywords: Acute respiratory distress syndrome, Antioxidants, Eicosapentaenoic acid, Enteral nutrition,
Gamma-linolenic acid, SepsisBackground
Acute onset of respiratory failure with protein-rich pul-
monary edema attributable to increased permeability of
alveolar epithelium and endothelial injury in pulmonary
vessels is the characteristic features of acute respiratory
distress syndrome (ARDS) [1].
Researchers have identified many of the inflammatory
mediators involved in the pathogenesis of ARDS and sep-
sis, including reactive oxygen species and lipid mediators* Correspondence: shu-chan@jf6.so-net.ne.jp
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unless otherwise stated.(e.g., eicosanoids) [2,3]. Eicosanoids play a role in both
pro- and anti-inflammatory reactions, depending on the
original fatty acids [4]. Pro-inflammatory eicosanoids ori-
ginate from n-6 fatty acids such as arachidonic acid (AA).
Competing with AA are eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA), which originate from n-3
fatty acids and produce eicosanoids that are less mark-
edly inflammatory and even anti-inflammatory [5]. Sup-
plementation with n-3 fatty acids (fish oil) reportedly
improves clinical outcomes in critically ill patients [4,6].
Furthermore, γ-linolenic acid (GLA) and dihomo-GLA
supplements reduce synthesis of pro-inflammatory AA
metabolites [7]. Additionally, strong promotion of oxi-
dation occurs during development of sepsis and ARDShis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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zinc, vitamin E, and vitamin C improves antioxidant cap-
acity, and thus outcomes, in critically ill patients [9].
Choice of nutritional supplement is particularly crucial in
sepsis-induced ARDS because the lungs are the major
sites of production of eicosanoids [10].
Three randomized controlled studies have reported clin-
ical benefits from administering enteral nutrition enriched
with EPA, GLA, and antioxidants in patients with ARDS
[11], acute lung injuries [12], severe sepsis, and septic
shock [13]. A meta-analysis showed that these nutritional
supplements reduce mortality, secondary infection, and
length of hospital stay [14]. However, these studies may be
biased in favor of the study groups because they received
n-3 fatty acids, which are metabolized into weakly inflam-
matory eicosanoids, whereas the control groups received
n-6 fatty acids, which are metabolized into more strongly
inflammatory eicosanoids. Furthermore, the patient groups
differed in their proportions of non-sepsis and sepsis-
related ARDS, which is important because these subgroups
have different prognoses [15-17]. Thus, the purpose of our
study was to compare the effects and safety of enteral diets
enriched with EPA, GLA, and antioxidants vs. standard
isocaloric and isonitrogenous diets in critically ill patients
with sepsis-induced ARDS.Methods
Study design
This study was a single-center, prospective, randomized,
single-blind, controlled trial conducted between March
2008 and March 2010 in the Advanced Critical Care
Center, Gifu University Hospital. The study protocol and
consent forms were approved by the institutional review
boards of Gifu University Hospital. Written informed con-
sent was obtained from all patients or their legal represen-
tatives before inclusion in the study.Study patients
Eligibility criteria were ages more than 18 years, receiv-
ing mechanical ventilation and able to be fed enterally
within 24 h of diagnosis of sepsis-induced ARDS. Diag-
noses of severe sepsis and septic shock were made ac-
cording to the criteria defined by the American College
of Chest Physicians/Society of Critical Care Medicine
Consensus Conference Committee [18]. ARDS was diag-
nosed according to the criteria defined by the American-
European Consensus Conference [19]. Multiple organ
dysfunction syndromes were evaluated by total Sequen-
tial Organ Failure Assessment (SOFA) scores [20]. After
inclusion, eligible patients were randomly assigned by a
principal investigator in a 1:1 ratio to either study or
control groups. For our exclusion criteria, please see
Additional file 1.Study protocol
Eligible patients were randomly allocated to two groups:
a study group that received an enteral diet enriched with
EPA, GLA, and antioxidants (Oxepa™; Abbott Nutrition,
Tokyo, Japan) and a control group that received a standard
isocaloric enteral diet (Ensure Liquid™; Abbott Nutrition,
Tokyo, Japan). The compositions of these diets are summa-
rized in Additional file 1. The study diet, a high-fat, low-
carbohydrate enteral formulation contained more calories
per 100 mL than the control diet. The control diet did not
contain EPA or GLA, and several antioxidants, such as vi-
tamins E and C, were in lower concentrations than in the
study diet. There were more carbohydrates in the control
diet than in the study diet.
The goal calories for both groups were set at 1.2 × basal
energy expenditure (BEE) calculated using the Harris Bene-
dict equation and adjusted to ideal body weight. The diets
delivered 70% of goal calories in the first week and 100%
within 14 days.
The day the enteral diets began was set as day 1. Gas-
tric or jejunal tubes were inserted as determined by the
principal investigator, with jejunal tubes being inserted
under fluoroscopic guidance. The diets were administered
continuously by infusion pumps starting within 24 h of
diagnosis of sepsis-induced ARDS. Enteral administration
was discontinued when oral intake became possible or
when the principal investigator decided to discontinue
them because of diet-related adverse events. Severe sepsis,
septic shock, and ARDS were treated in accordance with
the Surviving Sepsis Campaign Guidelines and ARDS Net-
work Low Tidal Volume Ventilation Protocol [21,22]. This
accordance includes our extubation process. We confirm
that this study has no influence on the decision of dis-
charge from ICU.
Data collection
The following data were collected for all patients: age, sex,
diagnostic category (medical, surgical, or trauma), baseline
comorbidities, Acute Physiology and Chronic Health
Evaluation (APACHE) II and total SOFA scores on diag-
nosis, number of organ failures, BMI, height, actual and
ideal body weights, 1.2 × BEE (goal calories), and calorie
intake on days 7 and 14. Because the enteral diets supply
relatively large amounts of fat, the following nutritional
variables were assessed once a week (days 1, 7, and 14):
total serum cholesterol, triglyceride, albumin, aspartate
transaminase, alanine transaminase concentrations, and
platelet count.
Outcome measures
The primary end point of this study was the duration of
mechanical ventilation. Secondary end points included
duration of ICU stay, changes over time in total SOFA
score, partial pressure of oxygen/fraction of inspired
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and 14), development of new nosocomial infections,
and all-cause mortality within 60 days of diagnosis. For
our weaning protocol and ICU discharge protocol, see
Additional file 1.
Statistical analysis
Data are expressed as percentages or medians with inter-
quartile ranges. When comparing two values in paren-
theses linked with “vs.”, the former value is for the control
and the latter is for the study group, unless otherwise
noted. All p values are two tailed; p < 0.05 is considered
statistically significant. All analyses were performed on an
intention-to-treat basis using IBM SPSS statistics version
19 (IBM, Somers, NY, USA). The Mann-Whitney U test
was used for continuous variables and Fisher’s exact test
for categorical variables. The intragroup proportions were
analyzed using a z-test with the Bonferroni adjustment.
To construct survival curves showing time to discontinu-
ation of ventilator support and time to discharge from the
Advanced Critical Care Center, the Kaplan-Meier sur-
vival analysis method with the log-rank (Mantel-Cox)
test was employed.
Results
Forty-six patients were eligible for this study, 23 of whom
received the study diet and the remainder received the
control diet. No patients were withdrawn from the study,
and the sole reason for the incomplete study was the77 patients were assessed for 
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Figure 1 Patient flow across the study. MV, mechanical ventilation.death (Figure 1). Relevant patient variables were compar-
able between the two groups, as shown in Table 1. There
were no significant differences in age, sex, reason for ad-
mission, and baseline comorbidities. The median APA-
CHE II and SOFA scores were not significantly different,
and the number of organ failures was similar in the two
groups. There were no significant differences between the
groups in infection sites, the most frequent being pulmon-
ary (16 patients altogether, 34.8%). The median starting
time for enteral nutrition was 20 h after meeting the inclu-
sion criteria in both groups. Both groups had achieved
their target calories by the seventh (70% of the goal cal-
ories) and fourteenth days (100% of the goal calories).
There were no significant differences between groups in
calorie or protein (51.0 g/day vs. 62.5 g/day) supplied by
day 14. The pathogenic bacteria causing ARDS are listed
in Table 2, and the definitive antibiotic therapy are
shown in Table 3.
The numbers of cases in which patients were admitted
due to septic ARDS were 16 in the study group and 10
in the control group. In passing, the standard diet was
fed enterally to all of the registered patients developing
septic ARDS during the ICU stay before starting the
study. Seven cases in the study group (30.4%) were in-
cluded because of septic ARDS developed during ICU
stay. The duration from the ICU admission to the onset
of septic ARDS was 8.0 days (median, IQR: 6.5–13.0) in
the study group. In the control group, there were 13
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Table 1 Relevant patient variables and baseline characteristics of patients enrolled in this study
Study group (n = 23) Control group (n = 23) p value
Age, years 71 (66–77) 74 (60–80) 0.717
Gender, n (%) 0.314
Male 15 (65.2) 19 (82.6)
Female 8 (34.8) 4 (17.4)
Reason for admission, n (%) 0.418
Medical 5 (21.7) 6 (26.1) NS
Elective surgery 6 (2.1) 4 (17.4) NS
Trauma 4 (17.4) 9 (39.1) NS
Emergency surgery 5 (21.7) 3 (13.0) NS
Burn 3 (13.0) 1 (4.3) NS
EN start time, hours 20 (8–24) 20 (8–24) 0.805
Catecholamine use, n (%) 16 (69.6) 14 (60.9) 0.758
Baseline comorbidities, n (%)
Hypertension 12 (52.2) 14 (60.9) 0.767
Cardiac disease 11 (47.8) 7 (30.4) 0.365
Diabetes mellitus 7 (30.4) 5 (21.7) 0.738
Oncological disease 2 (8.7) 4 (17.4) 0.665
Chronic obstructive pulmonary
disease
2 (8.7) 3 (13.0) 1.000
Chronic kidney disease 2 (8.7) 3 (13.0) 1.000
Cerebrovascular disease 2 (8.7) 3 (13.0) 1.000
Liver disease 1 (4.3) 1 (4.3) 1.000
APACHE II score on onset 24 (21–28) 23 (21–26) 0.860
SOFA score on onset 10 (6–13) 9 (8–13) 0.947
No. of organ failures, n (%) 0.274
1 8 (34.8) 6 (26.1) NS
2 6 (26.1) 12 (52.2) NS
3 7 (30.4) 3 (13.0) NS
4 2 (8.7) 2 (8.7) NS
Infection sites, n (%) 0.851
Pulmonary 7 (30.4) 9 (39.1) NS
Bacteremia 4 (17.4) 6 (26.1) NS
Abdomen 3 (13.0) 3 (13.0) NS
Soft tissue 2 (8.7) 2 (8.7) NS
Burn wound 3 (13.0) 1 (4.3) NS
Urinary tract 3 (13.0) 1 (4.3) NS
Others 1 (4.3) 1 (4.3) NS
Tidal volume, mL/kg 7.1 (6.6–7.8) 7.0 (6.3–8.4)
PEEP, cmH2O 11.0 (9.0–15.0) 11.0 (9.0–14.0)
Plateau airway pressure, cmH2O 28.2 (23.6–30.6) 26.8 (21.6–31.5)
Respiratory rate, breaths/min 23.0 (17.0–27.0) 22.0 (18.0–25.0)
Ejection fraction, % 62.4 (43.7–69.3) (n = 21) 61.3 (45.0–78.5) (n = 19)
Sivelestat sodium use, n (%) 21 (91.3) 19 (82.6)
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Table 1 Relevant patient variables and baseline characteristics of patients enrolled in this study (Continued)
Steroid use, n (%) 11 (47.8) 12 (52.2)
Sedation drugs
Midazolam use, n (%) 19 (82.6) 21 (91.3)
Propofol use, n (%) 3 (13.0) 2 (8.7)
Dexmedetomidine use, n (%) 4 (17.4) 4 (17.4)
Analgesics
Fentanyl, n (%) 15 (65.2) 13 (56.5)
Buprenorphine, n (%) 8 (34.8) 10 (43.5)
Actual body weight, kg 60 (55–66) 63 (58–66) 0.409
Ideal body weight, kg 59.9 (54.2–62.1) 59.9 (56.3–60.6) 0.930
Body mass index 23.2 (21.3–23.7) 23.1 (22.0–23.9) 0.684
Goal calories, kcal/day 1453.6 (1347.9–1574.0) 1454.2 (1364.5–1569.6) 0.956
Day 7 Day 14 Day 7 Day 14
Calorie intake, kcal/kg/daya 18.78 (18.12–20.21) 24.22 (23.32–25.90) 19.48 (15.73–20.68) 24.32 (22.67–25.75)
Protein intake, g/kg/dayb 0.781 (0.700–0.837) 0.988 (0.933–1.063) 0.613 (0.529–0.683) 0.810 (0.749–0.863)
NS Not Significant, EN Enteral Nutrition, APACHE Acute Physiology and Chronic Health Evaluation, SOFA Sequential Organ Failure Assessment, PEEP Positive
end-expiratory pressure. aThe difference at day 7 or day 14 is not statistically significant with p = 0.965 and p = 0.818, respectively; bThe differences at day 7 and
day 14 are both statistically significant (p < <0.001).
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cant according to the Fisher’s exact test (p = 0.136).
Primary and secondary outcomes
Table 4 shows the clinical outcomes. Duration of ICU
stay was the only outcome that significantly improved in






Methicillin-sensitive Staphylococcus aureus 3 5
Methicillin-resistant Staphylococcus aureus 2 3
Streptococcus pneumoniae 1 0
Streptococcus pyogenes 0 1
Enterococcus faecalis 1 1
Escherichia coli (ESBL) 6 (1) 3 (1)
Klebsiella pneumoniae 1 3
Haemophilus influenzae 0 2
Pseudomonas aeruginosa 6 1
Enterobacter cloacae 2 3
Serratia marcescens 0 1
Acinetobacter baumannii 0 1
Citrobacter koseri 0 1
Stenotrophomonas maltophilia 1 0
Prevotella species 0 2
Bacteroides species 3 2
Polymicrobial infection 3 3p = 0.015) with a power of 35%. Ten patients (43.5%) in
the study group had a relapse of infection, as did 12
patients (52.2%) in the control group. There were no
significant differences between groups in incidence of new
nosocomial infection or mortality (13.0% in both groups).
The primary outcome, duration of mechanical ventilation,
was shorter in the study than in the control group, but
this difference was not significant (17.0 [12.0–24.0] vs.
14.0 [10.0–17.0], p = 0.115) with a power of 9.7%. Survival
curves showing changes over time in number of patients
requiring ventilator support (Figure 2a) and patients
remaining in ICU (Figure 2b) are depicted in Figure 2. In
both graphs, the lines for the study group fall below those
for the other group. Thus, supplementation with n-3 fatty
acids tended to improve duration of mechanical ventila-
tion; however, this difference is not significant.
To evaluate the patients’ general conditions during the
study, changes over time in SOFA scores and oxygen-
ation status were assessed; these are plotted in Figure 3.
Since all of the patients survived the first 2 weeks, there
are no missing outcomes. SOFA scores decreased con-
sistently in both groups; there was no significant differ-
ence at each time point. The PaO2/FiO2 ratio differed
significantly only on day 7 (244.5 [197.5–295.8] vs. 297.0
[249.0–314.0], p = 0.021).
Nutritional variables and adverse effects
Assessed nutritional variables and adverse events are
shown in Table 5. For the first 7 days, the difference was
not significant between the groups, except for serum con-
centrations of bilirubin (0.7 [0.5–1.0] vs 1.1 [0.8–2.4)],
p = 0.009). Then, on day 14, the following three variables
Table 3 Definitive antibiotic therapy
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glyceride, and bilirubin. Neither vomiting nor abdominal
distension occurred during the observation period. Six pa-
tients in the study group (21.6%) and four in the control
group (17.4%) had mild, controllable diarrhea.
Discussion
In our study, supplementation with an enteral diet enriched
with EPA, GLA, and antioxidants did not shorten the dur-
ation of mechanical ventilation, improve SOFA scores, or
decrease the incidence of new nosocomial infections.
From the statistical analysis, the power of this trial turned
out to be very low for the primary outcome. It is very hard
to statistically conclude whether the null hypothesis of
no effect is actually true or not. From this analysis, we
could design a further trial with 126 patients (63 per
diet group) to detect 17.6% decrease of the duration ofTable 4 Clinical outcomes
Variable Study group (n = 23)
Duration of MV
Mean (SE, 95% CI) days 13.61 (1.00, 11.66–15.56)
Median (SE, 95% CI) days 14 (2.38, 9.34–18.66)
Ventilator-free daysb (median, IQR) 14 (11–18)
Duration of ICU stay
Mean (SE, 95% CI) days 17.6 3 (1.70, 14.30–20.97)
Median (SE, 95% CI) days 15 (3.19, 8.74–21.26)
ICU-free daysc (median, IQR) 13 (0–17)
Support free daysd
Renal replacement therapy, day 21 (0–24) (n = 7)
Catecholamine, day 26 (17.25–27) (n = 16)
Nosocomial infections, n (%) 10 (43.5)
Mortality, n (%) 3 (13.0)
CI confidence interval, MV mechanical ventilation, SE standard error, IQR interquarti
of Cox proportional-hazards model; bVentilator free days were defined as the numb
28. cICU-free days were defined as the number of days between successful discharg
between the last day supported and day 28.median mechanical ventilation (17 vs. 14) for a hazard
ratio of 1.21 with a power of 80%.
The only significant improvements in the study group
were in the duration of ICU stay and oxygenation status
on day 7. Even the effects of the study diet on the clin-
ical outcomes are minor; the effects to shorten ICU stay
length is rather clinically relevant (median: 15 [standard
error (SE): 3.19, 95% CI: 8.74–21.26] vs. median: 24 [SE:
1.82, 95% CI: 20.44–27.56]). The difference in median is
9 days, which is 37.5% reduction of the ICU stay. One
rational of this improvement may be that tracheotomy
was performed on more patients (13 cases) in the control
group than those (8 cases) in the study group. Although it
is not statistically significant, the length of the mechanical
ventilation support for the control group was longer than
that for the study group. As a result, more patients in the
control group underwent tracheostomy because 2-week
mechanical ventilation support is one of our criteria for
tracheostomy (our two criteria are listed in Additional
file 1). This difference could have caused the patients in
the control group to stay longer in ICU. Further investi-
gations are necessary to argue conclusively about the
mechanisms of this benefit.
Regarding the significant difference of P/F ratio at day
7 between the study group and the control group, we as-
sume that the anti-inflammatory effect of EPS, DHA,
and antioxidants actually helped improving the oxygen-
ation. Moreover, it is also known that n-6 fatty acid de-
lays oxygenation improvement. These effects might lead
to this significant distinction at day 7. The high variabil-
ity of P/F ratio at day 7 in the control group is caused by
only a few patients with relatively high oxygenation at









23 (14–25) (n = 7) 0.318
26 (18–27) (n = 14) 0.728
12 (52.2) 0.768
3 (13.0) 1.000
le range, ICU intensive care unit. aThe hazard ratio was calculated with the use
er of days between successful weaning from mechanical ventilation and day
e from ICU and day 28; dSupport free days were defined as the number of days
a b 
Figure 2 Survival curves generated by Kaplan-Meier survival analysis, representing primary and secondary clinical outcomes. (a) Duration of
mechanical ventilation. (b) Duration of ICU stay. The sole reason for censoring was that three patients in each group died before completing the
study (on days 14, 23, and 23 in the control group and on days 19, 21, and 21 in the study group). One patient in the control group died on day
23 but was extubated on day 22. Cum, cumulative.
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ICU stay. We speculate, however, that this significant
difference is rather tentative and does not directly contrib-
ute to the early discharge from ICU or the primary out-
comes of the mechanical ventilation support duration.a
Figure 3 Box plots of changes in SOFA scores and PaO2/FiO2 over time. C
1.5 × IQR of the upper quartile. (a) SOFA scores. The number of patients fo
day 14. (b) PaO2/FiO2 ratios. The numbers of patients analyzed for each da
(day 5), 23 vs. 22 (day 7), 18 vs. 21 (day 9), 12 vs. 14 (day 14), which is noteThe medians of the weaning date are much later, day 14
of day 17. It is hard to believe that the difference on the
day 7 solely affects the clinical outcomes 1 week later be-
cause that difference becomes statistically insignificant at
day 9 and 14. Note that this speculation is not conclusive,b 
ircles represent data below 1.5 × IQR of the lower quartile or above
r each day point is 23 for each group since the first censored case is at
y point are the following: 23 vs. 23 (day 1), 23 vs. 23 (day 3), 23 vs. 23
d as “the study group” vs. “the control group”.
Table 5 Hepatic and renal function
Study group Control group
Day 1 Day 7 Day 14 Day 1 Day 7 Day 14
Platelets 88 (43–149) 172 (131–282) 273 (191–343) 95 (86–136) 214 (117–263) 224 (134–369)
AST (IU/L) 24 (16–32) 24 (19–36) 30 (20–52) 29 (18–38) 26 (21–43) 39 (23–51)
ALT (IU/L) 35 (23–48) 32 (23–47) 33 (23–44) 43 (29–57) 33 (19–44) 32 (23–50)
Creatine (mg/dL)a 0.96 (0.81–2.12) 0.54 (0.45–0.84) 0.48 (0.36–0.63) 0.92 (0.67–2.65) 0.68 (0.56–0.90) 0.60 (0.51–0.67)
Triglyceride (mg/dL)b 79 (62–103) 85 (72–98) 110 (94–131) 76 (55–98) 91 (62–119) 92 (79–123)
Cholesterol (mg/dL) 84 (76–105) 103 (80–120) 126 (95–142) 93 (76–143) 103 (83–121) 107 (87–126)
Bilirubin (mg/dL)c 1.0 (0.5–1.8) 0.7 (0.5–1.0) 0.8 (0.6–0.9) 1.5 (1.0–2.6) 1.1 (0.8–2.4) 1.0 (0.7–1.5)
Albumin (g/dL) 2.3 (2.1–2.7) 2.5 (2.2–2.8) 2.9 (2.5–3.2) 2.4 (2.2–2.9) 2.5 (2.2–2.8) 2.7 (2.2–3.1)
Values are expressed as medians (IQR). AST aspartate transaminase, ALT alanine transaminase. ap = 0.048 for day 14; bp = 0.035 for day 14; cp = 0.009 for day 7 and
p = 0.028 for day 14.
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distinction of P/F ratio at day 7. In contrast to our an-
ticipation, enteral diets enriched with EPA, GLA, and
antioxidants did not significantly improve the outcomes
of sepsis-induced ARDS patients. We speculate that one
possible reason for this result is the low protein intake
at day 7 for both groups as shown in Table 1 (0.61 g/kg/
day [0.53–0.68] vs. 0.78 g/kg/day [0.70–0.84]). Our en-
teral nutrition protocol specifies a low initial adminis-
tration rate (70% of goal calories 1.2 × BEE in the first
week). In case of acute disease, a deficit of energy supply
(especially protein) in the first days could be crucial. On
the other hand, we assume that this low initial adminis-
tration rate might have contributed to our successful
completion of enteral diets without discontinuation due
to adverse effects such as uncontrollable gastrointestinal
complications. Enteral nutrition provided at a minimum
of 75% of goal calories for a minimum of 4 days reportedly
confers significant benefits; however, adverse effects cause
discontinuation of this regimen in some cases [11,13].
There is apparently an optimum rate that maximizes the
benefits of the nutritional formula by conferring high effi-
cacy and few and minor adverse effects.
Even though a systematic review concluded the benefi-
cial effects of the supplementation with n-3 fatty acids
[14], Grau-Carmona and colleagues [23] have demon-
strated that the only benefit of an enteral diet enriched
with these nutrients for critically ill patients with sepsis on
mechanical ventilation is decreasing the duration of ICU
stay. Their study is comparable with ours regarding study
patients, study procedures, and clinical outcomes. As
they discussed, the optimal dosage, timing, and nature
of supplemental nutrients in patients with sepsis require
clarification.
There are clinical trials reporting greater benefits
with n-3 fatty acid and antioxidant-enriched enteral di-
ets [11-13]. Although our findings do not support their
strongly positive conclusions, we agree that n-3 fatty
acid supplements have benefits for critically ill patients.Our argument concerns their choices of control diets.
Our control group received a standard formula in which
carbohydrates supply 54.5% of total calories; thus, n-6
fatty acids did not dominate our control diet. In contrast,
in the studies cited above, fats supplied 55.2% of total cal-
ories and carbohydrates only 28.1% in both groups. The
control diets in these studies were based on an enteral nu-
trition formula that is enriched with predominately n-6
fatty acids; these are metabolized into inflammatory eicos-
anoids [24,25]. Their study diets were enriched with n-3
fatty acids. The reported significant improvements in the
study groups are possibly attributable to the absence of n-
6 fatty acids in their diets. Moreover, their control groups
may have had particularly unfavorable clinical outcomes.
Even though our patients differed from those in the pre-
vious studies [11-13] in that they were older (70.2 years
vs. 58.7 years) and had lower PaO2/FiO2 (122.4 vs.
179.0) with respect to mean values, higher mean SOFA
scores (9.6 vs. 8.7), and more organ failures (2.09 vs.
1.45) as a mean value, the mortalities of the control
groups in those three studies were much higher than in
our control group (13.0% vs. 25–52%). We roughly esti-
mated the mean values cited in the previous sentence by
using the weighted means of the two groups in each trial.
These findings suggest that the high concentrations of n-6
fatty acids administered to the control groups in the previ-
ous studies adversely affected the patients.
In the recently published OMEGA study of Rice and
colleagues [26], enteral supplement with n-3 fatty acids,
GLA, and antioxidants did not improve clinical outcomes
or reduce inflammatory mediators in patients with acute
lung injury. These researchers terminated the study pre-
maturely because their first interim analysis suggested that
receiving these nutrients was not merely futile but may
even have been harmful. Although some of their results
accord with ours, our findings suggest that enteral sup-
plementation with n-3 fatty acids and antioxidants are
safe. This apparent discrepancy might be attributable to
their strategy of supplying n-3 fatty acids, GLA, and
Shirai et al. Journal of Intensive Care  (2015) 3:24 Page 9 of 10antioxidants by bolus feeding twice daily. In the OMEGA
study, there were more cases of gastrointestinal intoler-
ance manifested by diarrhea (28.7%) in the n-3 than in the
control group; some patients possibly failed to absorb the
supplemental nutrients adequately because of malabsorp-
tion. Malabsorption reportedly increases complications
because of protein-energy malnutrition [27,28]. Therefore,
supplying n-3 fatty acids in boluses may prejudice clarifi-
cation of their effects.
Moreover, in our study we started nutrients within
24 h of a patient meeting the inclusion criteria, whereas
in the OMEGA study, the starting time was up to 48 h
after inclusion. Polymorphonuclear leukocyte infiltrates
reportedly develop within 24 h when the lung is exposed
to lipopolysaccharide [29]. In addition, a recently published
study of patients in the early stages of sepsis without organ
failure has demonstrated that early enteral feeding with
EPA, GLA, and antioxidants decelerates progression to
more severe sepsis and organ failures [30]. It is possible
that early implementation of an enteral diet enriched
with pharmaconutrients reduces deterioration of organ
functions in patients with sepsis. Thus, the 24-hour dif-
ference between our study and the OMEGA study in
starting nutrients might also have contributed to their
differing conclusions.
We note that every patient registered is not admitted
due to septic ARDS. Some patients are included in this
study in the middle of their ICU stay since our inclusion
time is defined to be the onset of septic ARDS. Exclud-
ing patients admitted due to septic ARDS, the duration
from the ICU admission to the onset of the septic ARDS
was 8.0 days (median, IQR: 6.5–13.0) in the study group
and 5.0 days (median, IQR: 4.0–8.0). We believe that the
ICU stay of this length before developing septic ARDS
will cause little effect on the clinical outcomes once sep-
tic ARDS has been developed.
Our results may not be conclusive because we con-
ducted our study in a single-center with a single-blind
design, and the sample size was small. Nonetheless, our
study still indicates that enteral nutrition enriched with
n-3 fatty acid, GLA, and antioxidants has some benefits
in critically ill patients. It is yet unclear which administra-
tion protocols most effectively maintain constant plasma
concentrations of effective substances that are high enough
to be beneficial. Further investigations are needed to clarify
an optimum nutritional strategy with respect to admin-
istration route (enteral or parenteral or mixed), timing
(bolus or continuous), rate of administration, start
times, and the nutritional formula.
Conclusions
This study showed that an enteral diet enriched with
EPA, GLA, and antioxidants did not significantly improve
duration of mechanical ventilation, total SOFA score,incidence of new nosocomial infections, and mortality in
critically ill patients with sepsis-induced ARDS. However,
we did demonstrate the benefits of significantly shorter
duration of ICU stay and a trend toward moderately redu-
cing duration of mechanical ventilation.
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